Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
The discovery could also help pave the way for new treatments for lacunar strokes, which are caused by damage to the tiny ...
Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...
Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...
CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...
Severe bleeding after trauma can rapidly become life-threatening. In a new doctoral thesis from Karolinska Institutet, Marcus ...
Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for ...
For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” ...
Severe bleeding after trauma can rapidly become life-threatening. In a new doctoral thesis from Karolinska Institutet, Marcus ...
Compared with the prior quarter’s gross-to-net framing of “the high 30s for 2026,” CFO Mardi Dier updated the range to “the mid- to high 30s for the rest of 2026,” citing improved visibility after Q1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results